Most cited papers in Peroxisome Proliferator-Activated Receptors
What are the most cited papers in Peroxisome Proliferator-Activated Receptors?
The most cited paper in Peroxisome Proliferator-Activated Receptors is "Nitric Oxide and Peroxynitrite in Health and Disease" (Pál Pacher, Joseph S. Beckman, Lucas Liaudet, 2007), with 6,382 citations. Next come "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance" (5,834) and "A Receptor-Mediated Pathway for Cholesterol Homeostasis" (5,742).
Showing 50 of 99 papers. Every paper with more than 1,314 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Nitric Oxide and Peroxynitrite in Health and Disease Pál Pacher, Joseph S. Beckman, Lucas Liaudet · Physiological Reviews | 2007 | 6,382 |
| 2 | Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance Haiyan Xu, Glenn T. Barnes, Qing Yang et al. · Journal of Clinical Investigation | 15 Dec 2003 | 5,834 |
| 3 | A Receptor-Mediated Pathway for Cholesterol Homeostasis Michael Scott Brown, Joseph L. Goldstein · Science | 4 Apr 1986 | 5,742 |
| 4 | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes Steven E. Nissen, Kathy Wolski · New England Journal of Medicine | 22 May 2007 | 4,695 |
| 5 | SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver Jay D. Horton, Joseph L. Goldstein, Michael Scott Brown · Journal of Clinical Investigation | May 2002 | 4,328 |
| 6 | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial John Dormandy et al. · The Lancet | Oct 2005 | 4,157 |
| 7 | Prostaglandins and Inflammation Emanuela Ricciotti, Garret A. FitzGerald · Arteriosclerosis Thrombosis and Vascular Biology | 20 Apr 2011 | 3,833 |
| 8 | Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology Colin D. Funk · Science | 30 Nov 2001 | 3,829 |
| 9 | An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) Jürgen M. Lehmann, Linda B. Moore, Tracey A. Smith-Oliver et al. · Journal of Biological Chemistry | Jun 1995 | 3,648 |
| 10 | Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor Peter Tontonoz, Erding Hu, Bruce M. Spiegelman · Cell | Dec 1994 | 3,551 |
| 11 | The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation Mercedes Ricote, Andrew C. Li, Timothy Mark Willson et al. · Nature | 1998 | 3,545 |
| 12 | Discovery and refinement of loci associated with lipid levels Cristen J. Willer et al. · Nature Genetics | 6 Oct 2013 | 3,319 |
| 13 | Mitochondrial Diseases in Man and Mouse Douglas C. Wallace · Science | 5 Mar 1999 | 3,076 |
| 14 | Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Steven E. Kahn, Steven M. Haffner, Mark A. Heise et al. · New England Journal of Medicine | 4 Dec 2006 | 2,968 |
| 15 | PPAR-γ agonists inhibit production of monocyte inflammatory cytokines Chengyu Jiang, Adrian T. Ting, Brian Seed · Nature | 1998 | 2,909 |
| 16 | Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism* Béatrice Desvergne, Walter Wahli · Endocrine Reviews | Oct 1999 | 2,903 |
| 17 | 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ BARRY MARC FORMAN, Peter Tontonoz, Jasmine Chen et al. · Cell | Dec 1995 | 2,866 |
| 18 | Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Anna Meiliana, Andi Wijaya · PubMed | Sep 1998 | 2,736 |
| 19 | Identification of a Nuclear Receptor for Bile Acids Makoto Makishima, Arthur Y. Okamoto, Joyce J. Repa et al. · Science | 21 May 1999 | 2,723 |
| 20 | The Mechanisms of Action of PPARs Joel P. Berger, David E. Moller · Annual Review of Medicine | Feb 2002 | 2,684 |
| 21 | AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α Sibylle Jäger, Christoph Handschin, Julie St‐Pierre et al. · Proceedings of the National Academy of Sciences | 3 Jul 2007 | 2,489 |
| 22 | GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects Da Young Oh, Saswata Talukdar, Eun Ju Bae et al. · Cell | Sep 2010 | 2,443 |
| 23 | Understanding Adipocyte Differentiation Francine M. Gregoire, Cynthia M. Smas, Hei Sook Sul · Physiological Reviews | 7 Jan 1998 | 2,410 |
| 24 | Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Kristin M. Nieman, Hilary A. Kenny, Carla V. Penicka et al. · Nature Medicine | 30 Oct 2011 | 2,326 |
| 25 | Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators Julie St‐Pierre, Stavit Drori, Marc Uldry et al. · Cell | Oct 2006 | 2,251 |
| 26 | mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Peter Tontonoz, Elise Hu, Reed A. Graves et al. · Genes & Development | 15 May 1994 | 2,189 |
| 27 | Cellular Fatty Acid Metabolism and Cancer Erin Currie, Almut Schulze, Rudolf Zechner et al. · Cell Metabolism | 20 Jun 2013 | 2,179 |
| 28 | Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Steven A. Kliewer, Scott S. Sundseth, Stacey A. Jones et al. · Proceedings of the National Academy of Sciences | 29 Apr 1997 | 2,169 |
| 29 | Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Olivier Braissant, Fabienne Foufelle, Christian Scotto et al. · Endocrinology | 1996 | 2,161 |
| 30 | Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ BARRY MARC FORMAN, Jasmine Chen, Ronald M. Evans · Proceedings of the National Academy of Sciences | 29 Apr 1997 | 2,122 |
| 31 | Macrophage-specific PPARγ controls alternative activation and improves insulin resistance Justin Iver Odegaard, Roberto R. Ricardo-González, Matthew H. Goforth et al. · Nature | 21 May 2007 | 2,112 |
| 32 | Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Norikazu Maeda, Iichiro Shimomura, Ken Kishida et al. · Nature Medicine | 17 Jun 2002 | 2,099 |
| 33 | Fat and Beyond: The Diverse Biology of PPARγ Peter Tontonoz, Bruce M. Spiegelman · Annual Review of Biochemistry | 20 Mar 2008 | 2,097 |
| 34 | Nuclear Receptors and Lipid Physiology: Opening the X-Files Ajay Chawla, Joyce J. Repa, Ronald M. Evans et al. · Science | 30 Nov 2001 | 2,096 |
| 35 | PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro Evan D. Rosen, Pasha Sarraf, Amy E. Troy et al. · Molecular Cell | Oct 1999 | 2,089 |
| 36 | Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α (PGC-1α): Transcriptional Coactivator and Metabolic Regulator Pere Puigserver, Bruce M. Spiegelman · Endocrine Reviews | Feb 2003 | 2,085 |
| 37 | The Enzymes, Regulation, and Genetics of Bile Acid Synthesis David W. Russell · Annual Review of Biochemistry | Jun 2003 | 2,075 |
| 38 | Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome Gregory G. Schwartz, ANDERS G. OLSSON, Markus Abt et al. · New England Journal of Medicine | 5 Nov 2012 | 2,055 |
| 39 | A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation Steven A. Kliewer, James M. Lenhard, Timothy Mark Willson et al. · Cell | Dec 1995 | 2,035 |
| 40 | PPARγ signaling and metabolism: the good, the bad and the future Maryam Ahmadian, Jae Myoung Suh, Nasun Hah et al. · Nature Medicine | May 2013 | 2,029 |
| 41 | Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases Artemis P. Simopoulos · Journal of the American College of Nutrition | Dec 2002 | 2,016 |
| 42 | Roles of PPARs in health and disease Sander Kersten, Béatrice Desvergne, Walter Wahli · Nature | May 2000 | 1,972 |
| 43 | Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ Robert T. Nolte, G. Bruce Wisely, Stefan K. Westin et al. · Nature | Sep 1998 | 1,965 |
| 44 | PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development Yaacov Barak, Michael C. Nelson, Estelita S. Ong et al. · Molecular Cell | Oct 1999 | 1,957 |
| 45 | Transcriptional regulation of adipogenesis Evan D. Rosen, Christopher J. Walkey, Pere Puigserver et al. · Genes & Development | Jun 2000 | 1,904 |
| 46 | Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening K. K. Srinivasan, Bhoomi Viswanad, Lydia Asrat et al. · Pharmacological Research | 25 Jun 2005 | 1,888 |
| 47 | Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ Laszlo Tibor Nagy, Peter Tontonoz, Jacqueline G. A. Alvarez et al. · Cell | Apr 1998 | 1,874 |
| 48 | Apolipoprotein E: Far More Than a Lipid Transport Protein Robert W. Mahley, Stanley C. Rall · Annual Review of Genomics and Human Genetics | Sep 2000 | 1,862 |
| 49 | Thiazolidinediones Hannele Yki‐Järvinen · New England Journal of Medicine | 8 Sep 2004 | 1,827 |
| 50 | PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL Peter Tontonoz, Laszlo Tibor Nagy, Jacqueline G. A. Alvarez et al. · Cell | Apr 1998 | 1,819 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.